Drugs / Metatinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02650375 | Oct 2015 → Oct 2017 | colorectal cancer, liver cancer, non-small cell lung carcinoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02650375 ↗ |
| Known as | Metatinib Tromethamine | “Study of Metatinib Tromethamine Tablet” NCT02650375 ↗ |
| Route | Oral | “Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.” NCT02650375 ↗ |